2 months ago
PMN
AnalystsEddie HickmanEddie Hickman's Stock Forecasts
AnalystsEddie Hickman
Sectors:
Industries:
Analyst Ranking
Top 14%
#781 out of 5511 analysts
Average Return
+29.39%
Win Rate
73%22 out of 30
Risk vs Reward
Poor
Good
Eddie Hickman's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Iveric Bio IncISEE | +167.40% | $14.94 | $39.95 | 2022-09-07 - 2023-07-10 | Strong Buy |
Tarsus Pharmaceuticals IncTARS | +137.07% | $16.13 | $38.24 | 2023-05-18 - 2024-05-17 | Strong Buy |
Cybin IncHELP | +133.04% | $5.63 | $13.12 | 2025-12-03 - 2026-09-15 | Strong Buy |
Ataibeckley IncATAI | +87.53% | $3.85 | $7.22 | 2026-01-20 - 2026-07-17 | Strong Buy |
Tarsus Pharmaceuticals IncTARS | +85.16% | $16.98 | $31.44 | 2023-09-11 - 2024-09-10 | Strong Buy |
Eddie Hickman Analyst Color
Get additional color on Eddie Hickman's coverage of popular stocks
5 months ago
ATAI
7 months ago
TARS
9 months ago
HELP
2 years ago
ZVRA
Eddie Hickman's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Zevra Therapeutics IncZVRA | 5 | Strong Buy | $23.00 | +97.42% | Maintains | a month ago |
Gh Research PLCGHRS | 2 | Strong Buy | $40.00 | +45.19% | Maintains | a month ago |
Promis Neurosciences IncPMN | 5 | Strong Buy | $69.00 | +435.30% | Maintains | 2 months ago |
Ataibeckley IncATAI | 3 | Hold | N/A | N/A | Downgrades | 2 months ago |
Tarsus Pharmaceuticals IncTARS | 10 | Strong Buy | $90.00 | +15.05% | Maintains | 7 months ago |
Cybin IncHELP | 2 | Strong Buy | $48.00 | +265.85% | Maintains | 9 months ago |
Outlook Therapeutics IncOTLK | 4 | Hold | N/A | N/A | Downgrades | a year ago |
Iveric Bio IncISEE | 2 | Hold | N/A | N/A | Downgrades | 3 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.